India Alzheimers Drug Market Size, Share, Growth, and Industry Analysis, By Drug Class (Cholinesterase Inhibitors Donepezil Rivastigmine Galantamine, NMDA Receptor Antagonists Memantine, Combination Drugs Donepezil + Memantine, Anti-Amyloid Monoclonal AntibodiesLecanemab (Leqembi) Aducanumab (Aduhelm) Donanemab (under review) ), By Disease Stage  (Early Stage / Mild Alzheimer€™s, Moderate Alzheimer€™s, Severe Alzheimer€™s, Prodromal / Mild Cognitive Impairment (MCI) ) and Forecast, 2026-2034

India Alzheimers Drug Market Trends

Shift Toward Disease-Modifying and Earlier-Stage Therapy

India’s treatment landscape is shifting beyond established oral symptomatic drugs toward biomarker-guided anti-amyloid therapy. In August 2026, Eisai launched LEQEMBI (lecanemab) in India following CDSCO marketing authorization for MCI and mild dementia due to early Alzheimer’s. India has an estimated 8.8 million people aged 60+ living with dementia, corresponding to approximately 7.4% prevalence, with the burden projected to nearly double by 2036.

Technology adoption increasingly incorporates amyloid confirmation, MRI surveillance and infusion-based treatment pathways. Lecanemab targets aggregated amyloid-beta, while global evidence has accelerated investment in disease-modifying approaches. In 2025, the FDA recommended an additional MRI before the third lecanemab infusion, supplementing monitoring before the 5th, 7th and 14th infusions, highlighting the infrastructure requirements accompanying advanced therapy adoption.

India Alzheimers Drug Market Drivers

Rising Dementia Burden and Earlier Diagnosis

India’s ageing population creates a substantial treatment pool, with approximately 8.8 million adults aged 60+ estimated to have dementia and prevalence near 7.4%. The number of affected people is projected to nearly double by 2036. Meanwhile, disease-modifying therapy is moving treatment intervention toward MCI and mild dementia, expanding emphasis on biomarker testing, neurology consultation and longitudinal monitoring.

India Alzheimers Drug Market Restraints

Complex Safety Monitoring and Treatment Infrastructure

Advanced anti-amyloid therapy requires infrastructure beyond conventional tablet dispensing. MRI monitoring is central because amyloid-related imaging abnormalities can include edema and hemorrhagic events. FDA guidance for lecanemab includes MRI assessment before multiple infusions, including an additional scan before the 3rd infusion and established monitoring before the 5th, 7th and 14th infusions. These requirements increase specialist, imaging and infusion-center intensity relative to conventional oral therapy.

India Alzheimers Drug Market Opportunities

Disease Modification Expands the Treatable Early-Stage Population

The introduction of lecanemab creates a new commercial pathway for patients with MCI or mild dementia due to Alzheimer’s disease. CDSCO’s April 2026 committee documentation records a proposed Phase IV multicentre postmarketing study of lecanemab 100 mg/mL in routine Indian clinical practice. This provides an opportunity for neurologists, diagnostic providers and hospitals to establish integrated amyloid-confirmation, infusion and safety-monitoring pathways.

Challenges in India Alzheimers Drug Market

Balancing Clinical Benefit, Accessibility and Safety

Disease-modifying therapy remains operationally more demanding than traditional symptomatic treatment. Globally, lecanemab received U.S. approval in 2023, donanemab in 2024, while aducanumab was commercially discontinued in 2024. Anti-amyloid treatment therefore combines therapeutic progress with safety, patient-selection and access challenges. India must accommodate repeated dosing, MRI capacity and specialist supervision while addressing a dementia population estimated at 8.8 million people aged 60+.

India Alzheimers Drug Market Segmentation

Drug class concentration remains substantial: cholinesterase inhibitors account for 40.16% of the 2026 drug-class total, while early/mild Alzheimer’s represents 40.14% of disease-stage revenue. The supplied dataset provides quantitative forecasts for drug class and disease stage; other segmentation dimensions are assessed structurally without introducing unsupported revenue estimates.

By Drug Class

Cholinesterase inhibitors are the largest class, increasing from USD 69.19 million in 2025 to USD 73.66 million in 2026 and USD 121.54 million in 2034 at 6.46% CAGR. Donepezil, rivastigmine and galantamine constitute the principal subcategories.

NMDA receptor antagonists rise from USD 38.61 million in 2026 to USD 63.28 million by 2034 at 6.37% CAGR. Combination drugs reach USD 56.73 million at 6.22%, anti-amyloid monoclonal antibodies USD 42.71 million at 6.00%, and tau aggregation inhibitors USD 14.83 million at 5.94% by 2034.

By Disease Stage

Early stage/mild Alzheimer’s leads at USD 73.55 million in 2026 and is projected at USD 119.28 million in 2034, registering 6.23% CAGR. Its 2026 contribution is approximately 40.14% of the disease-stage total.

Moderate Alzheimer’s advances from USD 46.34 million to USD 74.64 million at 6.14% CAGR, while severe disease increases from USD 43.89 million to USD 71.02 million at 6.20%. Prodromal/MCI records 6.23% CAGR and reaches USD 31.56 million by 2034.

By Mechanism of Action

The segmentation includes amyloid-beta inhibitors, tau protein modulators, neurotransmitter modifiers, anti-inflammatory agents, mitochondrial stabilizers and synaptic-function enhancers. Quantified mechanism-specific revenues were not supplied; therefore no unsupported market values are assigned.

The therapeutic transition is increasingly relevant to amyloid-directed mechanisms, while neurotransmitter modification remains established through cholinesterase and NMDA pathways. The supplied quantitative tables cover 5 drug classes and 4 disease stages rather than mechanism-level revenues.

By Drug Type

Drug type is divided into biologics and small molecules. Small molecules encompass established oral symptomatic therapies, while biologics increasingly represent disease-modifying anti-amyloid monoclonal antibodies.

No biologics-versus-small-molecules revenue split was provided. The supplied framework nevertheless identifies 2 distinct drug-type categories serving different administration, monitoring and patient-selection requirements.

By Distribution Channel

Distribution comprises hospital pharmacies, retail pharmacies and online pharmacies. Hospital channels are particularly relevant to infusion-led biologics, while retail channels support recurring oral prescriptions.

The framework contains 3 distribution channels, but channel-specific revenue and CAGR figures were not supplied. Consequently, quantitative drug-class and disease-stage values are not redistributed across these channels.

By End User

End users include hospitals, specialty clinics and neurology centers, homecare settings, and academic and research institutions. Hospitals and neurology centers are central to diagnosis, infusion administration and MRI-linked safety management.

The segmentation covers 4 end-user categories. No end-user revenue series was provided, so numerical allocation across these settings is intentionally excluded to preserve consistency with the mandatory source dataset.

India Alzheimers Drug Market Counties Outlook

India is the geographic scope of the supplied dataset. The national drug-class total increases from USD 172.55 million in 2025 to USD 183.42 million in 2026 and USD 299.09 million in 2034 at 6.20% CAGR. Cholinesterase inhibitors account for 40.16% of 2026 revenue, versus 21.05% for NMDA antagonists and 19.09% for combination drugs.

State, zone and city-level production or revenue contributions were not provided and are therefore not fabricated. At national level, early/mild disease contributes 40.14% of the 2026 disease-stage total, compared with 25.29% for moderate disease, 23.95% for severe disease and 10.62% for prodromal/MCI.

Top players in India Alzheimers Drug Market

• Eisai Co., Ltd.
• Biogen Inc.
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Torrent Pharmaceuticals Ltd.
• Lupin Ltd.
• Eli Lilly and Company
• Pfizer Inc.
• Novartis AG
• Zydus Lifesciences Ltd.
• Intas Pharmaceuticals Ltd.

Top Two Companies

• Eisai Co., Ltd.

Company-specific India revenue share was not supplied and is therefore not estimated. Eisai holds a strategically differentiated position following the August 2026 Indian launch of LEQEMBI for MCI and mild dementia due to Alzheimer’s. CDSCO documentation also records a Phase IV postmarketing study proposal involving lecanemab 100 mg/mL. This positions Eisai prominently within the emerging disease-modifying biologics segment.

• Sun Pharmaceutical Industries Ltd.

Company-specific percentage share is unavailable in the mandatory dataset. Sun Pharma maintains an established CNS portfolio in India containing memantine products such as ADMENTA, donepezil formulations such as DONETAZ, and donepezil-plus-memantine products under DONAMEM. Its portfolio therefore spans multiple established symptomatic-treatment mechanisms and dosage strengths.

Recent Developments in India Alzheimers Drug Market

• 2026:Eisai launched LEQEMBI in India after CDSCO marketing authorization for early Alzheimer’s disease, including MCI and mild dementia.
• 2026:CDSCO committee records documented Eisai’s proposed multicentre Phase IV postmarketing lecanemab study in India.
• 2025:The U.S. FDA recommended additional MRI monitoring before the 3rd lecanemab infusion because of ARIA-E risk.
• 2025:European marketing authorization for Leqembi was issued on April 15, following the November 2024 positive opinion.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period. Mandatory supplied values were retained as the primary quantitative source: USD 172.55 million in 2025, USD 183.42 million in 2026 and USD 299.09 million in 2034 for the drug-class total, with a stated 6.20% CAGR. Percentage contributions were calculated directly from supplied values. Public regulatory, company and clinical sources were used only for qualitative context and recent developments; unavailable state-level, company-share, production-volume and untabled segment forecasts were not fabricated.